ACOG Menu

These frequently asked questions (FAQs) cover new information and requirements for clinicians offering Nexplanon. The recently announced Risk Evaluation and Mitigation System (REMS) requirement, described below, applies to all clinicians who procure, insert, or remove Nexplanon.

The American College of Obstetricians & Gynecologists strongly recommends early certification to avoid disruptions in patient access to this highly effective long-acting contraceptive.

Download as a PDF

 

Frequently Asked Questions

References

Nexplanon® (etonogestrel implant), for subdermal use. Highlights of prescribing information. Organon; 2026. Accessed May 11, 2026. https://www.organon.com/product/usa/pi_circulars/n/nexplanon/nexplanon_pi.pdf

Organon. Nexplanon REMS. Accessed May 11, 2026. https://www.nexplanonrems.com/

Reed S, Do Minh T, Lange JA, Koro C, Fox M, Heinemann K. Real world data on Nexplanon® procedure-related events: final results from the Nexplanon Observational Risk Assessment study (NORA). Contraception 2019;100:31–6. doi: 10.1016/j.contraception.2019.03.052


This information is designed as an educational resource to aid practitioners in assessing their patients’ needs, and use of this information is voluntary. This information should not be considered as inclusive of all proper treatments or methods of care or as a statement of the standard of care. It is not intended to substitute for the independent professional judgment of the treating clinician. Variations in practice may be warranted when, in the reasonable judgment of the treating clinician, such course of action is indicated by the condition of the patient, limitations of available resources, or advances in knowledge or technology. The American College of Obstetricians and Gynecologists reviews its publications regularly; however, its publications may not reflect the most recent evidence. Any updates to this document can be found on www.acog.org  or by calling the ACOG Resource Center.